0000950170-23-018401.txt : 20230505
0000950170-23-018401.hdr.sgml : 20230505
20230505180056
ACCESSION NUMBER: 0000950170-23-018401
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230503
FILED AS OF DATE: 20230505
DATE AS OF CHANGE: 20230505
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AGENUS INC
CENTRAL INDEX KEY: 0001098972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40908
FILM NUMBER: 23895281
BUSINESS ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-674-4410
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER NAME:
FORMER CONFORMED NAME: ANTIGENICS INC /DE/
DATE OF NAME CHANGE: 19991115
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MiNK Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840229
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 149 FIFTH AVENUE
STREET 2: SUITE 500
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 212-994-8250
MAIL ADDRESS:
STREET 1: 149 FIFTH AVENUE
STREET 2: SUITE 500
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: AgenTus Therapeutics, Inc.
DATE OF NAME CHANGE: 20210112
4
1
ownership.xml
4
X0407
4
2023-05-03
0001840229
MiNK Therapeutics, Inc.
INKT
0001098972
AGENUS INC
3 FORBES ROAD
LEXINGTON
MA
02421
false
false
true
false
false
Common Stock
2023-05-03
4
P
false
128689
1.0789
A
21473374
D
Common Stock
2023-05-04
4
P
false
21473
1.2223
A
21494847
D
Common Stock
2023-05-05
4
P
false
100000
0.9485
A
21594847
D
Common Stock
2023-05-05
4
P
false
200
1.25
A
21595047
D
Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $0.9144 to $1.20).
Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.
Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $1.20 to $1.25).
On May 5, 2023, Agenus purchased 100,000 shares of MiNk Therapeutics, Inc. common stock from Garo Armen, Agenus's Chairman and CEO, at the same price he paid to acquire the shares on May 2, 2023. The acquisition price represents a 40% discount to the market price as of today's market close.
/s/ Christine Klaskin, Vice President, Finance
2023-05-05